Physician profile
Michael Rezak
NPI 1003975897
$183,817.69
in general payments reported to CMS, 2019-2025
17 companies · $472 in 2025
The $472 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46K · 2020: $30K · 2021: $53K · 2022: $38K · 2023: $15K · 2024: $468 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $1,530 · Consulting Fee: $1,100 · Education: $111 · Travel and Lodging: $35.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,520.00 |
| Food and Beverage | $1,529.80 |
| Consulting Fee | $1,100.00 |
| Education | $111.45 |
| Travel and Lodging | $35.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $53,231.33 | 2019-2025 | |
| Kyowa Kirin, INC. | $47,218.62 | 2020-2024 | Nourianz |
| Mdd US Operations, LLC | $23,947.77 | 2020-2025 | Gocovri, Gocovri, Apokyn |
| Amneal Pharmaceuticals LLC | $20,285.18 | 2020-2025 | Rytary, Crexont |
| Acadia Pharmaceuticals INC | $11,078.24 | 2022-2024 | Nuplazid |
| Lundbeck LLC | $10,934.86 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $6,400.00 | 2020-2021 | |
| Medtronic, INC. | $3,287.71 | 2022-2025 | Percept PC Brainsense, Sensight |
| Boston Scientific Corporation | $3,167.76 | 2019-2022 | |
| Ucb, INC. | $1,503.64 | 2019 | |
| Acorda Therapeutics, INC | $1,365.00 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $435.48 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Medtronic USA, INC. | $404.24 | 2019 | |
| Neurocrine Biosciences, INC. | $304.65 | 2022-2025 | Ingrezza, Ongentys |
| Alexion Pharmaceuticals, INC. | $124.88 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $111.01 | 2019-2023 | Infinity |
| Allergan, INC. | $17.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rezak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.